Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Portfolio Pulse from Lisa Levin
Insiders at Satsuma Pharmaceuticals, Erasca, and Aprea Therapeutics have been aggressively buying shares, indicating confidence in their respective companies. Satsuma Pharmaceuticals recently announced FDA acceptance of its STS101 migraine treatment, while Erasca discontinued its ERAS-007 programs, and Aprea Therapeutics posted a narrower quarterly loss.
June 09, 2023 | 11:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Erasca's Chairman and CEO bought shares after the company announced it would not continue exploring its ERAS-007 programs.
Erasca's decision to discontinue its ERAS-007 programs may have mixed implications for the company. However, the CEO's purchase of shares indicates confidence in the company's future prospects, suggesting a neutral short-term impact on the stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Aprea Therapeutics' Director bought shares after the company posted a narrower quarterly loss.
Aprea Therapeutics' narrower quarterly loss is a positive sign for the company. The Director's purchase of shares indicates confidence in the company's prospects, which could lead to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Insiders at Satsuma Pharmaceuticals bought shares after the FDA accepted its STS101 migraine treatment.
The FDA acceptance of Satsuma Pharmaceuticals' STS101 migraine treatment is a positive development for the company. Insider buying indicates confidence in the company's prospects, which could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100